January 2026
Hepatic cholate clearance as assessed by HepQuant-SHUNT is predictive of clinical outcomes in individuals with Fontan circulation
Yuli Y. Kim, Daniel Ganger, Alexis Z. Tomlinson, Isabella Z. Farkas, Jack Rychik, Joanne Imperial, Michael P. McRae, Greg T. Everson, Maarouf A. Hoteit | International Journal of Cardiology Congenital Heart Disease
Fontan-associated liver disease [FALD] is universal in individuals with Fontan circulation [FC]. The dual cholate clearance test is a noninvasive, flow-dependent measure of liver function. We aim to explore the association between cholate clearance and clinical outcomes in this population. read more →
January 2026
HepQuant DuO® Test Enhances Clinical Decision Making in Compensated Advanced Chronic Liver Disease
Kerry Whitaker, Joanne C. Imperial, Michael P. McRae, and Gregory T. Everson | Journal of Clinical Medicine | January 2026
The HepQuant DuO® test is a noninvasive, blood-based test that assesses global liver health by quantifying liver function and physiology. The test generates a disease severity index (DSI) for assessment of risk for portal hypertension and large esophageal varices (LEV) to aid in the upper endoscopy (EGD) decision, provides a definition of disease severity to aid in clinical management, and enables serial testing to monitor changes in liver health over time, either improvement or worsening.
A DSI cutpoint 18.3 was defined in a U.S. multi-center trial in advanced chronic hepatitis C (HALT-C) and validated in a second U.S. multi-center trial where the majority of cases (52%) had MASLD/MASH (SHUNT-V). In addition, the latter validation study included all common etiologies of cACLD, and a high percentage of the study subjects were overweight, obese, elderly, and had diabetes. In several studies, DSI has shown favorable diagnostic performance compared to other noninvasive tests.
Using real-world data, the analysis evaluated the impact of DSI 18.3 in the EGD
decision and in modifying decision making in patients with cACLD. read more →
November 2025
Cholate clearance: improving the assessment of liver health compared to current liver tests (LFTs)
James R. Burton, Jr., MD, Edward Mena, MD, Bhaktasharan Patel, MD | Gastro Hep Advances | November 2025
Current liver function tests (LFTs) either indicate late-stage disease or hepatobiliary injury but do not accurately measure liver function. True quantitative liver function tests, analogous to creatinine clearance for the kidneys, are needed for assessing liver health.
read more →
Coming Soon
Scientific Research: Posters & Presentations
The Quantitative HepQuant DuO Test Uncovers the Functional Heterogeneity of Advanced Chronic Liver Disease
Author: J.C. Imperial, M.P. McRae, and G.T. Everson
Event: 9th Annual MASH Drug Development Summit
Simultaneous quantification of function of native human liver and porcine liver in an extracorporeal circuit derived from the blood concentrations of intravenously injected 13C-cholate
Author: Abraham Shaked, Michael P. McRae, Joanne C. Imperial, Leanne Lanieri, Alexander Sagar, Kathryn C. Stiede, Kirsten G. Swenson, Peter Friend, Gregory T. Everson
Event: DDW 2025 Presentation
Pilot Study of a Model Based on Noninvasive Assessments of Portal-Systemic Shunting (HepQuant DuO), Hepatic Fibrosis (FibroScan), and Splenic Congestion (Platelet Count) for Accurate Prediction of Portal Hypertension and Clinically Significant Portal Hypertension
Author: J.C. Imperial, M.P. McRae, and G.T. Everson
Event: Liver Connect | March 2025
Resmetirom Therapy of MASH-Associated Child Pugh A Cirrhosis Reduces Estimated Risk for Clinical Outcome Based on HepQuant RISK ACE Model
Author: J.C. Imperial, M.P. McRae, R. Taub, and G.T. Everson
Event: Liver Connect | March 2025
Quantifying Liver Function by Cholate Clearance in Extracorporeal Circuits with a Genetically Modified Porcine Liver and Brain-Dead Human Decedent
Author: A. Shaked, M.P. McRae, L. Lanieri, A. Sagar, K.C. Stiede, K.G. Swenson, P. Friend, G.T. Everson
Event: EASL May 2025
Coming Soon
Professional Organizations
Coming Soon
- American Association for the Study of Liver Disease (AASLD)
- American Gastroenterological Association (AGA)
- American College of Gastroenterology (ACG)
- American Society of Transplantation (AST)
- American Society of Pediatric Gastroenterology and Nutrition (NASPGHAN)
- European Association for the Study of the Liver (EASL)
- Asian Pacific Association for the Study of the Liver (APASL)
- International Liver Transplant Society (ILTS)
- American Heart Association (AHA)
- American Cancer Society (ACS)